Zobrazeno 1 - 10
of 33
pro vyhledávání: '"AI TOYODOME"'
Autor:
Ai Toyodome, Seiichi Mawatari, Hiromi Eguchi, Midori Takeda, Kotaro Kumagai, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Masanori Ikeda, Akio Ido
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (o
Externí odkaz:
https://doaj.org/article/3fe6eb0227284a16be2ea8103fd1f582
Autor:
Kotaro Kumagai, Shuji Kanmura, Seiichi Mawatari, Yuko Nakamura, Hiromi Eguchi, Oki Taniyama, Ai Toyodome, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Keita Shimata, Taizo Hibi, Akio Ido
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Background: Glycoprotein non-metastatic melanoma protein B (GPNMB) is expressed in macrophages during recovery from acute liver injury (ALI) in carbon tetrachloride (CCl4)-induced liver injury model mice. In this retrospective study, we assessed whet
Externí odkaz:
https://doaj.org/article/a1f40279821e4041848a49127e33c2db
Autor:
Seiichi Mawatari, Kotaro Kumagai, Kohei Oda, Kazuaki Tabu, Sho Ijuin, Kunio Fujisaki, Shuzo Tashima, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Masafumi Hashiguchi, Tsutomu Tamai, Takeshi Hori, Ohki Taniyama, Ai Toyodome, Haruka Sakae, Takeshi Kure, Kazuhiro Sakurai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido
Publikováno v:
PLoS ONE, Vol 17, Iss 1 (2022)
Background The features of hepatitis C virus patients with a sustained virologic response (SVR) who developed hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) therapy are unclear. Methods The study population included 1494 DAA-SVR p
Externí odkaz:
https://doaj.org/article/a9d631c3572b48d2b03ea489655c1018
Autor:
Ai Toyodome, Seiichi Mawatari, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Kotaro Kumagai, Takashi Tasaki, Akio Ido
Publikováno v:
Clinical Journal of Gastroenterology. 16:416-421
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6827b7798453c44897673b83ff53481
https://doi.org/10.1007/s12328-023-01771-4
https://doi.org/10.1007/s12328-023-01771-4
Autor:
Kazuaki Tabu, Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Masafumi Hashiguchi, Tsutomu Tamai, Takeshi Hori, Kunio Fujisaki, Dai Imanaka, Takeshi Kure, Ohki Taniyama, Ai Toyodome, Sho Ijuin, Haruka Sakae, Kazuhiro Sakurai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237475 (2020)
Background and aimsDirect-acting antivirals (DAAs) against hepatitis C virus (HCV) exert high anti-HCV activity and are expected to show anti-inflammatory effects associated with HCV elimination. Furthermore, hepatocellular carcinoma (HCC) is known t
Externí odkaz:
https://doaj.org/article/77e19cc7fd2f44569864b15ba39951ef
Autor:
Seiichi Mawatari, Tsutomu Tamai, Kotaro Kumagai, Akiko Saisyoji, Kaori Muromachi, Ai Toyodome, Ohki Taniyama, Haruka Sakae, Sho Ijuin, Kazuaki Tabu, Kohei Oda, Yasunari Hiramine, Akihiro Moriuchi, Kazuhiro Sakurai, Shuji Kanmura, Akio Ido
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6139
The present study clarified the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) followed by transcatheter arterial chemoembolization (TACE) on demand. We retrospectively evaluated 88 intermediate-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50198fea70a444cdbfe9bfbfa1da0c4d
https://pubmed.ncbi.nlm.nih.gov/36551623
https://pubmed.ncbi.nlm.nih.gov/36551623
Autor:
Ai Toyodome, Tsutomu Tamai, Fumisato Sasaki, Masafumi Hashiguchi, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Kotaro Kumagai, Seiichi Mawatari, Akio Ido
Publikováno v:
Internal Medicine; 2023, Vol. 62 Issue 12, p1749-1755, 7p
Autor:
Sho, Ijuin, Kohei, Oda, Seiichi, Mawatari, Ohki, Taniyama, Ai, Toyodome, Haruka, Sakae, Kazuaki, Tabu, Kotaro, Kumagai, Shuji, Kanmura, Tsutomu, Tamai, Akihiro, Moriuchi, Hirofumi, Uto, Akio, Ido
Publikováno v:
Molecular and Clinical Oncology
The prevalence of non-alcoholic fatty liver disease (NAFLD) is continuously increasing, with the proportion of patients with liver carcinogenesis due to non-alcoholic steatohepatitis (NASH) rising accordingly. Although it is important to identify ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3400fa57a409654c06ee8e7f3456de25
https://doi.org/10.3892/mco.2021.2488
https://doi.org/10.3892/mco.2021.2488
Autor:
Sho Ijuin, Kotaro Kumagai, Ai Toyodome, Shuji Kanmura, Kazuaki Tabu, Akio Ido, Kohei Oda, Ohki Taniyama, Seiichi Mawatari, Haruka Sakae
Publikováno v:
Molecular and Clinical Oncology
Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein (hs-AFP-L3) is a specific marker for hepatocellular carcinoma (HCC) and has been reliable in cases with a low serum α-fetoprotein (AFP) level. However, the biomarkers tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65afee4df1761f98295aaae39117b69f
https://doi.org/10.3892/mco.2021.2336
https://doi.org/10.3892/mco.2021.2336
Autor:
Kohei Oda, Dai Imanaka, Shuji Kanmura, Tsutomu Tamai, Kotaro Kumagai, Akio Ido, Yukiko Inada, Ohki Taniyama, Kazuhiro Sakurai, Takeshi Hori, Hirofumi Uto, Akihiro Moriuchi, Seiichi Mawatari, Takeshi Kure, Ai Toyodome, Akiko Saisyoji, Haruka Sakae, Kunio Fujisaki, Masafumi Hashiguchi, Yasunari Hiramine, Sho Ijuin, Kazuaki Tabu
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237475 (2020)
PLoS ONE
PLoS ONE
Background and aimsDirect-acting antivirals (DAAs) against hepatitis C virus (HCV) exert high anti-HCV activity and are expected to show anti-inflammatory effects associated with HCV elimination. Furthermore, hepatocellular carcinoma (HCC) is known t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1d5c9e213bf13ea97c3c35ff45b5c5
https://doaj.org/article/77e19cc7fd2f44569864b15ba39951ef
https://doaj.org/article/77e19cc7fd2f44569864b15ba39951ef